Stock Price Forecast

March 25, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Cassava Sciences Inc chart...

About the Company

refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.

$36M

Total Revenue

29

Employees

$832M

Market Capitalization

-26.02

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SAVA News

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava Sciences

21h ago, source:

If you suffered losses exceeding $100,000 investing in Cassava stock or options between August 18, 2022 and October 12, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner ...

Cassava Sciences: New Year, Same Game Of Smoke And Mirrors

3d ago, source:

Cassava Sciences reported 2023 cash of $121.1m, $(97.2m) of net loss and R&D expenses increased to $89.4m. Read more on SAVA ...

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

3d ago, source:

The DSMB is composed of independent clinical research experts who periodically review interim patient safety data for Cassava Sciences’ on-going Phase 3 trials of simufilam in Alzheimer’s disease.

Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go?

11d ago, source:

Cassava Sciences presented different charts at the CTAD and Lisbon conferences, causing speculation about the reasons for the ...

Cassava Sciences again under scrutiny over Alzheimer's drug research

on MSN ago, source:

A lab run a City University of New York (CUNY) scientist with ties to Cassava Sciences (NASDAQ:SAVA) and its Alzheimer's ...

(SAVA) - Analyzing Cassava Sciences's Short Interest

7d ago, source:

Cassava Sciences's SAVA short percent of float has fallen 3.46% since its last report. The company recently reported that it ...

Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report

on MSN ago, source:

The credibility of the clinical trial results for an experimental Alzheimer's drug has been called into question following a ...

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline...

12d ago, source: Macau Business

Class Action, Consumer Services, GlobeNewswire, Law & Legal Issues | NEW YORK, (GLOBE NEWSWIRE) -- WHY: Rosen Law ...

SAVA Mar 2024 17.000 put

12d ago, source: Yahoo Finance

AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a ...

SAVA Apr 2024 20.000 call

13d ago, source: Yahoo Finance

AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a ...

Cassava: How Nutrition Professionals Assess Its Health Benefits, Nutrition Facts, And More

17h ago, source: Microsoft Start Health on MSN

CherubinBachelor in Nutrition · 5 years of experience · ArgentinaBenefits Cassava helps digestion. It is very easy to digest ...

SAVA Apr 2024 20.500 put

10d ago, source: Yahoo Finance

AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...